2004

• Named among worldwide biotechnology companies ranked by percentage of total revenue devoted to R&D in Leaders of Life Science magazine.
• Frank Baldino, Jr. honored with the Chester County Economic Development Council’s Hall of Fame Award for outstanding achievements.
• Named to the 2004 edition of The Forbes 2000, a comprehensive list of the world’s biggest and most powerful companies.
• PROVIGIL® (modafinil) Tablets [C-IV] listed by Drug Topics as number 113 among top 200 branded drugs in 2003, measured by retail dollars spent on prescriptions.
• Harvard Medical School Endowed Chair Named after Frank Baldino, Jr., Ph.D.
• Ranked by MedAdNews in “Top 10 Biotechnology Companies” list based on total revenues.
• Included in the Fortune 40—A Model Portfolio with the Best Investment Ideas for the Year Ahead.
• Named for the second consecutive year to the Deloitte & Touche Technology Fast 50 and the Fast 500 lists based on percentage of revenue growth over five years.

2003

• Named to the Forbes 500 list, a report card on how the biggest and most profitable companies perform.
• Listed on the Forbes list of Fastest Growing Technology Companies.
• Ranked among the top 10 “Most Admired Biotechnology Companies” by MedAdNews.
• Inducted into the Biotech Hall of Fame in the Best of Biotech 2003 Awards.
• Named "Entrepreneurial Company of the Year" by the Great Valley Chamber of Commerce.
• Named to the Deloitte & Touche Technology Fast 50 and the Fast 500 lists based on percentage of revenue growth over five years.
• Ranked by The Scientist magazine as one of the "Top 10 Best Places to Work."

2002

• Selected to join the NASDAQ 100.
• Received the Deloitte & Touche Technology Fast 50 award as one of the fifty fastest-growing companies in America.
• Received the National Sleep Foundation Corporate Award for work in sleep medicine.
• Recognized by Invest in France and the French-American Chamber of Commerce.
• Honored by the Eastern Technology Council as Life Science Company of the Year.